Intravenous immunoglobulin in the treatment of paediatric cerebral malaria.
Hyperimmune globulin can inhibit and reverse the cytoadherence between Plasmodium falciparum-infected erythrocytes and melanoma cells in vitro. Cytoadherence is believed to mediate disease in cerebral malaria. Therefore we studied the efficacy of i.v. immunoglobulin, purified from the plasma of local semi-immune blood donors, as an adjunct to standard treatment for cerebral malaria in Malawian children. The immunoglobulin preparation (IFAT antimalarial antibody titre 1:5120) recognized erythrocyte-associated antigens of each of 22 Malawian P. falciparum isolates studied, and reversed binding of Malawian isolates to melanoma cells. Immunoglobulin did not reverse binding to human monocytes or to cells of the human histiocytic lymphoma cell line U937. Thirty-one children with P. falciparum parasitaemia and unrousable coma were enrolled. All were treated with i.v. quinine dihydrochloride; in addition patients were randomized to receive either immunoglobulin (400 mg/kg by i.v. infusion over 3 h) or placebo (albumen and sucrose by similar infusion) in a double blind trial with sequential analysis. Of 16 patients receiving immunoglobulin, five (31%) died and five survivors had neurological sequelae. Of 15 patients receiving placebo, one (7%) died and two had sequelae. Parasite clearance, fever clearance and coma resolution times in survivors were similar in the two groups. Although the difference in outcome between the two groups was not significant, the trial was stopped because immunoglobulin was demonstrated not to be superior to placebo.
Taylor
T E
TE
Department of Paediatrics, Queen Elizabeth Central Hospital, Blantyre, Malawi.
Molyneux
M E
ME
Wirima
J J
JJ
Borgstein
A
A
Goldring
J D
JD
Hommel
M
M
D002448:Cell Adhesion; D002648:Child; D002675:Child, Preschool; D003165:Complement System Proteins / Q000032:analysis*; D004912:Erythrocytes / Q000469:parasitology; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007167:Immunotherapy; D007223:Infant; D016779:Malaria, Cerebral / Q000097:blood / Q000473:pathology / Q000628:therapy*; D016778:Malaria, Falciparum / Q000097:blood / Q000473:pathology / Q000628:therapy*; D008297:Male
D016756:Immunoglobulins, Intravenous; D003165:Complement System Proteins